ALNYLAM PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 152.3 USD | +1.34% |
|
+6.29% | -20.42% |
| May. 02 | Alnylam Pharmaceuticals' Q1 Non-GAAP Net Loss Narrows as Revenue Increases; 2024 Outlook Affirmed | MT |
| May. 02 | Transcript : Alnylam Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 02, 2024 |
Financials (USD)
| Sales 2024 * | 1.87B | Sales 2025 * | 2.27B | Capitalization | 19.27B |
|---|---|---|---|---|---|
| Net income 2024 * | -475M | Net income 2025 * | -244M | EV / Sales 2024 * | 9.63 x |
| Net cash position 2024 * | 1.26B | Net cash position 2025 * | 508M | EV / Sales 2025 * | 8.27 x |
| P/E ratio 2024 * |
-42.5
x | P/E ratio 2025 * |
-80.7
x | Employees | 2,100 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.15% |
More Fundamentals
* Assessed data
More news
Latest transcript on Alnylam Pharmaceuticals, Inc.
More recommendations
More press releases
More news
| 1 day | +1.34% | ||
| 1 week | +6.29% | ||
| Current month | +5.82% | ||
| 1 month | +0.56% | ||
| 3 months | -11.98% | ||
| 6 months | -8.98% | ||
| Current year | -20.42% |
1 week
143.50
155.41
1 month
141.98159.34
Current year
141.98199.38
1 year
141.98218.88
3 years
117.58242.97
5 years
65.81242.97
10 years
31.38242.97
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 61 | 16-09-18 | |
Jeffrey Poulton
DFI | Director of Finance/CFO | 56 | 19-08-12 |
Piyush Sharma
CMP | Compliance Officer | - | 22-09-20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 15-12-17 |
Charles Sigal
BRD | Director/Board Member | 72 | 22-08-21 |
Margaret Hamburg
BRD | Director/Board Member | 68 | 19-01-09 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 5.08% | 1 M€ | -4.80% | - | |
| 4.04% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 152.3 | +1.34% | 452,160 |
| 24-05-02 | 150.3 | +0.23% | 660,180 |
| 24-05-01 | 150 | +4.18% | 735,892 |
| 24-04-30 | 144 | -2.31% | 477,045 |
| 24-04-29 | 147.4 | +2.83% | 439,862 |
Delayed Quote Nasdaq, May 03, 2024 at 04:30 pm EDT
More quotes
Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Companyâs lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
Calendar
2024-05-16
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
152.3
USD
Average target price
220.2
USD
Spread / Average Target
+44.55%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.42% | 19.27B | |
| +25.69% | 47.86B | |
| +46.90% | 41.42B | |
| -3.46% | 40.66B | |
| -6.20% | 28.92B | |
| +9.17% | 25.55B | |
| +0.17% | 12.15B | |
| +28.07% | 12.14B | |
| -1.24% | 11.99B | |
| +19.33% | 11.64B |
- Stock Market
- Equities
- ALNY Stock
